GET DAILY SIGNALSWhy Is NeuroPace (NPCE) Stock Down -48.42% Today?
Key Takeaways
- NPCE shares plunged 48.42%, or $5.82, to $6.20 in early trading Friday, against Thursday's close of $12.02.
- The primary catalyst was a wide third-quarter revenue miss paired with a sharp cut to full-year 2026 revenue guidance.
- Secondary pressure came from a wave of analyst downgrades and price-target cuts, including Leerink's move to Market Perform with a $7 target.
- Healthcare and biotech benchmarks were only modestly lower, so the decline reflects company-specific news rather than sector-wide selling.
- News Significance Score: 87/100 — major guidance cut and downgrades meet a roughly 20x normal price swing.
- Volume was already about 2.5 times the average full session within the first 15 minutes of trading.
- Traders are now focused on fourth-quarter implant cadence, the resubmission timeline for the IGE indication, and the pace of commercial recovery heading into 2027.
- For deeper research, explore Price Targets, Earnings, and Forecast pages.
- Review the strongest automated strategies in the Trending AI Robots section.
NeuroPace Stock Collapses After Guidance Reset
NeuroPace, Inc. (NPCE) is a Mountain View, California-based medical device company whose RNS System delivers brain-responsive neuromodulation to patients with drug-resistant focal epilepsy. The stock fell 48.42% to $6.20 in morning trading, down from Thursday's close of $12.02 — a decisive move lower that erased roughly half the company's market value in a single session.
The immediate cause is unambiguous: results reported after Thursday's close showed third-quarter revenue well below expectations, and management reset its full-year outlook. No ambiguity surrounds the direction of the move.
Q3 Revenue Miss and a Full-Year Guidance Cut
Third-quarter revenue came in at $23.1 million, down 1.1% year over year and roughly 15% below the $27.1 million consensus. RNS System revenue of $22.9 million grew just 1.4%, a stark deceleration from the low-20s growth rates the company posted in the first half of the year.
Non-GAAP loss per share of $0.10 matched expectations, gross margin improved to 84.8% from 82.8%, operating expenses declined, and adjusted EBITDA turned modestly positive. Those offsets were irrelevant to the market reaction.
The decisive item was guidance. NeuroPace cut its 2026 revenue range to $91 million–$92 million from $99.5 million–$101.5 million, a reduction of roughly 9% and far larger than the quarterly shortfall itself. Management attributed the gap to disruption from a reorganized sales force and field clinical team, operational issues at several high-volume accounts, and the lingering commercial impact of exiting the SEEG distribution business, which had provided regular operating-room access to neurosurgeons. The company trimmed its operating expense outlook and raised its gross margin target, but a wider adjusted EBITDA loss range of $8.5 million–$9.5 million confirmed that the growth trajectory, not the cost base, is the problem.
Analyst Downgrades Amplify the Selling
The guidance reset was reinforced Friday morning by rating actions. Leerink cut NPCE to Market Perform from Outperform and slashed its price target to $7 from $20, calling the quarter "clearly disappointing" and pointing to poor commercial execution in high-volume accounts. Wells Fargo moved to Equal Weight from Overweight with a $9 target, and KeyBanc trimmed its target to $14 from $18 while maintaining Overweight. That broke a previously unanimous bullish consensus and removed the buy-side support that had anchored the stock near $12.
Market Context and Trading Activity
Volume confirmed conviction behind the move. Roughly 313,000 shares changed hands in the first 15 minutes of Friday's session, compared with a 20-day average near 127,000 for a full day.
The decline was entirely idiosyncratic. The iShares Biotechnology ETF fell about 1.2%, the Health Care Select Sector SPDR slipped 0.2%, and the Invesco QQQ Trust was down 0.5%. LivaNova, the closest listed comparable in neuromodulation, traded essentially flat. No peer or sector sympathy selling occurred.
Technically, the stock gapped below its prior 52-week low of $11.90 and now sits far beneath its 50-day moving average near $13.35 and 200-day average near $14.80. Early trading established a range of roughly $6.05 to $7.07, with the opening print near $6.25 representing an immediate 48% repricing rather than a gradual breakdown.
News Significance Score
The score runs from 0, meaning no meaningful news and a move that is normal for the stock, to 100, meaning transformative news and an extreme, rare price move. NPCE earns 87 out of 100.
The verified news was substantial: a 15% revenue miss, a guidance cut of roughly 9%, and multiple downgrades against a company valued at about $400 million before the drop. The price move was equally extreme — roughly 20 times the stock's typical daily swing of about 2.5%, with no comparable session in the past 60 trading days. Strong news plus a rare move produces the high score.
What Comes Next for NPCE
Attention shifts to fourth-quarter implant cadence, which management says has begun to recover, and whether the sales force changes translate into volume before the next report. The company is preparing an amendment to its IGE indication submission around year-end 2026, enrolling the AURORA real-world evidence study in adolescent focal epilepsy, and awaiting FDA review of its Remote Care submission. Those catalysts remain intact but are now discounted more heavily.
Risks include further account-level disruption, reimbursement pressure, and a rate environment that is unkind to loss-making small-cap growth names. Analyst expectations have reset sharply, and the consensus view is no longer uniformly constructive.
Trending AI Robots
Tickeron operates hundreds of AI trading bots covering thousands of tickers, but only the strongest performers under current market conditions appear in the curated Trending AI Robots section. Bots differ by strategy, timeframe, performance metrics, and traded symbols, so the lineup rotates as conditions change. For traders navigating volatile single-stock moves like this one, reviewing the current leaderboard is a practical starting point.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Momentum Indicator for NPCE turns negative, indicating new downward trend
NPCE saw its Momentum Indicator move below the 0 level on November 10, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 98 similar instances where the indicator turned negative. In 89 of the 98 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Moving Average Convergence Divergence Histogram (MACD) for NPCE turned negative on November 12, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In 45 of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NPCE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
NPCE broke above its upper Bollinger Band on October 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for NPCE entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where NPCE's RSI Oscillator exited the oversold zone, 23 of 25 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
Following a +0.85% 3-day Advance, the price is estimated to grow further. Considering data from situations where NPCE advanced for three days, in 236 of 279 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 17 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: NPCE's P/B Ratio (36.106) is slightly higher than the industry average of (4.142). P/E Ratio (-21.930) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (4.427) is also within normal values, averaging (40.124).
The Tickeron PE Growth Rating for this company is 20 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 70 (best 1 - 100 worst), indicating slightly worse than average price growth. NPCE’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NPCE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry MedicalNursingServices
Advertisement